The Impact of Chemotherapy after Pediatric Malignancy on Humoral Immunity to Vaccine-Preventable Diseases
Pediatric Hematology Oncology, Azienda Ospedaliera Universitaria Integrata Verona, Italy.
2 Microbiology and Virology Unit, Azienda Ospedaliera Universitaria Integrata Verona, Italy.
3 Microbiology and Virology Unit, Padova University Hospital, Padova, Italy.
4 Ospedale di San Bonifacio, Azienda AULSS 9 Scaligera, Verona, Italy.
Received: November 30, 2019
Accepted: February 9, 2020
Mediterr J Hematol Infect Dis 2020, 12(1): e2020014 DOI 10.4084/MJHID.2020.014
| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The antibody titer of vaccine-preventable disease in pediatric patients
who underwent chemotherapy was assessed in order to evaluate the
seroprotection after treatment and the feasibility and the efficacy of
a policy of revaccination.
Patients with malignancies have an elevated risk of infections, some of them preventable by active immunization, e. g. invasive pneumococcal diseases. This augmented susceptibility is related to the immune impairment due to the disease itself or the therapies (chemotherapy, radiotherapy).[3–5] Chemotherapy causes a transient immunodeficiency that lasts for about 6 months after the end of the treatment. Moreover, in patients who undergo haemopoietic stem cell transplantation (HSCT), humoral and cellular immunity is affected by chemotherapy and radiotherapy used in the conditioning regimen, and by immunosuppressive treatment used to prevent graft rejection and graft versus host disease.
International guidelines recommend revaccination from at least 3-6 months after the end of chemotherapy, and from 3-6 to 12-24 months after HSCT.
In this study, we assessed patients’ vaccination status at the diagnosis of malignancy, comparing it to that of a healthy population. Moreover, the persistence of protective antibody titer was followed-up after the end of chemotherapy in order to apply a re-vaccination protocol and assess its efficacy in restoring vaccination immunity.
Material and Methods
|Table 1. Vaccination Protocol of the Pediatric Hematology and Oncology Unit, Verona.|
Serologic assays. Antibodies detection for HBV, rubella, VZV, measles, mumps, polio viruses, C. tetani, and S. pneumoniae were conducted on fresh serum samples using commercial kits and following the manufacturer’s instructions. Chemiluminescence technology (CLIA) was used to detect rubella, measles, mumps, VZV IgG (Diasorin S.p.A., Saluggia, Vercelli, Italy) and HBsAg antibodies (Siemens Healthcare Diagnostics, Inc., Tarrytown, NY, US); enzyme immuno assay (EIA) was used for C. tetani IgG (Diasorin S.p.A., Saluggia, Vercelli, Italy) and for S. pneumoniae IgG (The Binding Site Group Ltd, Birmingham, UK); neutralization assay, according to WHO guidelines, was used for poliovirus. Results were interpreted as positive, negative or undetermined according to kit instructions. Positive results were considered as follow: HbsAg antibodies > 12 mUI/ml, rubella IgG > 10 UI/mL, VZV IgG > 135 mUI/mL, measles IgG > 16,5 AU/mL, mumps IgG > 9 AU/mL, C. tetani IgG > 0,51 UI/mL, poliovirus IgG > 1:8. For S. pneumoniae were considered positive results IgG titers >35 mg/L, in accordance with WHO recommendation. Specifically, the kit used measures antibody responses to pneumococcal vaccines incorporating 23 polysaccharides isolated from S. pneumoniae.
Statistical analysis. Collected data were analyzed using descriptive statistics: median and range for continuous variables, absolute frequency, and percentages for categorical or dichotomous variables.
Differences of quantitative variables between groups were texted using the non-parametric Kruskal-Wallis test, whereas categorical variables using the Chi-squared test or Fisher’s exact test.
The following variables were tested in univariate analysis for the loss of protective serum antibody titers: sex, type of diagnosis, age at diagnosis, time from the end of chemotherapy.
A P-value of <0,05 was considered statistically significant. Analysis was conducted using the statistical software SAS, 9.4 version (Statistical Analysis Software, SAS Institute Inc.).
The term lack of immunity was used for patients with non-protective antibody titers if they were tested after chemotherapy. The term loss of immunity was used for patients tested pre- and post- treatment and had a change of the antibody level from positive to negative. Seroprotection was defined by any level of antibody positivity, including a borderline positivity with an undetermined titer.
|Table 2. Demographic and clinical characteristics of study patients.|
Antibody titers at diagnosis. At diagnosis, the complete serological panel of antibodies against HBV, rubella, VZV, measles, mumps, polio viruses, and C. tetani was available only for 11 of 55 patients, whereas 4 patients did not perform any antibody determination. The most missing data were antibodies against poliovirus (available only for 22 patients) and C. tetani (available for 15 patients). In table 3, data of seroprotection in the study population at the diagnosis (median age: 5.9 years) were compared to regional vaccination coverage (VC) in a healthy population of at the latest 8 years old.
|Table 3. Seroprotection of study population at the diagnosis and comparison to vaccination coverage of healthy population of the same median age.|
Some patients lack protective immunity at diagnosis, in detail, 11 patients (24%) for HBV, 6 (14%) for rubella virus, 11 (26%) for VZV, 4 (9%) for measles virus, 7 (16%) for mumps virus, 1 (6%) for poliovirus and 7 (54%) for C. tetani. The lack of seroprotection was related to the fact that patients were not vaccinated in 1/11 for HBV, 2/6 for rubella virus, 5/11 for VZV, 2/4 for measles virus, and 2/7 for the mumps virus.
Lack of protective serum antibody titers after chemotherapy. Fifty-five patients assessed the antibody titers after a median time of 26 months from the end of chemotherapy. The rate of the lack of protective serum antibody titers for HBV, rubella, VZV, measles, mumps, polio viruses, C. tetani and S. pneumoniae is presented in table 4. Data differ by type of vaccine and underlying malignancy, ranging from 27-36% for poliovirus to 89% for C. tetani in the group with hematological malignancies and from 8% for poliovirus to 85% of patients for C. tetani in solid tumors group.
|Table 4. Rates of lack of protective serum antibody titer in patients tested after chemotherapy.|
Loss of protective serum antibody titers after chemotherapy. In patients tested both before and after chemotherapy, rates of protective antibody titers loss for HBV, rubella, VZV, measles, mumps, polio viruses, and C. tetani are summarized in table 5. Rates vary depending on vaccine type: from 32% of patients for mumps virus to 80% for C. tetani.
|Table 5. Rate of loss of protective antibody titers after chemotherapy in patients tested both before and after chemotherapy.|
Univariate analysis for the loss of protective serum antibody titer is given in table 6. No factor was statistically significant.
|Table 6. Univariate analysis of factors associated with loss of immunity after chemotherapy.|
The comparison between the number of CD3+, CD4+, CD8+ and CD19+ lymphocytes determined after chemotherapy and average values for age, i.e., 5-10 years old, is shown in table 7.
|Table 7. Comparison between lymphocyte subpopulations in peripheral blood of study patients after chemotherapy and healthy controls.|
In univariate analysis, a lower number of B-lymphocytes resulted significantly associated with the loss of protective antibody titer for measles virus, p=0.04, whereas a higher number of CD8+ T-lymphocytes was significantly associated with the loss of antibody protection for VZV, p=0.03.
Antibody titers after vaccination protocol application. Revaccination with a single-shot vaccination boost of 10 patients who underwent chemotherapy obtained the restoration of protective serum antibody level in 2 out of 3 patients for HBV, in 5 out of 6 patients for rubella virus, in 4 out of 5 patients for VZV, in 4 out of 6 patients for measles virus, in 2 out of 6 patients for mumps virus, in 8 out of 8 patients for poliovirus, in 7 out of 8 patients for C. tetani and in 2 out of 3 patients for S. pneumoniae.
In this study, data of protective immunity due to vaccination were not available for every patient, especially for C. tetani and poliovirus. This reflects a local problem because these testes were not performed at the hospital laboratory, and, if requested by the physician in charge, the serum samples had to be sent to laboratories outside, increasing the costs.
When the rate of patient seroprotection at the diagnosis was compared to the vaccination coverage in a healthy population, significant differences were seen for HBV (respectively 76% vs. 95%), poliovirus (94-100% vs. 90%), and C. tetani (46% vs. 91%). We underline that seroprotection figures in the study patients were calculated on the basis of antibody determinations, whereas in the general population, this index is based just on the administration of vaccination, irrespective of efficacy in terms of seroprotection. Therefore, the data on regional vaccination coverage for vaccines could not correspond to the efficacy of vaccination, intended as the documentation of a protective antibody titer after vaccination. Moreover, the differences could also be attributed to the small sample size. Considering the ideal immunization coverage recommended by World Health Organization in the health population to provide herd immunity, i.e., 95%, it emerged that patients’ immunization coverage was far from this value, except from polio (95-100%).
One of our principal purposes was to analyze the impact of chemotherapy on vaccine humoral immunity. We demonstrated that patients were prone to loose protective antibody titer, acquired by vaccination, or in some cases by natural infection. As a result, the patients after chemotherapy are frequently not protected against vaccine-preventable diseases, and this fact can be relevant when the patients return to school or in the community. In the case of outbreaks, like the measles outbreak which affected Italy in 2017, these patients would be hugely at risk.
In literature, the loss of protective antibody titers after chemotherapy is frequent, even if percentages of loss or lack of immunity vary depending on the study considered, ranging from 25-88% for measles virus, 26-88% for mumps virus, 19-88% for rubella virus,[14–16] 17-35% for VZV,[14,17] 11.6-14% for C. tetani,[15,18] 7% for poliovirus, and 26-86% for HBV.[15,16,19,20] In patients with Acute Lymphoblastic Leukemia, non-protective antibody levels were seen in 2-80% patients for C. tetani, 0-38% for poliovirus, 8-71% for mumps virus, 40-71% for measles virus and 8-28% for rubella virus. Although these studies are heterogeneous, most of them were performed with patients with hematological malignancies, whereas our study included both hematological and solid tumors.
The risk factor analysis for the loss of immunity did not find any association with sex, type of diagnosis, age at diagnosis, and time from the end of chemotherapy, although we highlight that the sample was small. Interestingly, we showed that a low number of CD19+ lymphocytes was associated with the loss of protective antibody titer against measles virus. This observation is in line with the finding that patients treated with B-depleting monoclonal antibodies, such as rituximab, have lower responses to vaccination for at least 6 months after the end of treatment.[22,23] We also found that a high number of CD8+ lymphocytes is associated with the loss of immunity against VZV. This finding needs to be confirmed further.
In order to evaluate the role of the immune recovery in the persistence or the loss of vaccine immunity after therapies, the peripheral blood subpopulations of lymphocytes were assessed, and no differences were found between study patients and healthy children of the same age. We hypothesize that the re-exposure to vaccine antigens has a crucial role in vaccine immunity reconstitution in order to induce the appearance and proliferation of lymphocytes capable of mounting a specific humoral response again. For this reason, our policy was to revaccinate the patients starting from 6 months from the end of treatments. Forty-six percent of patients were compliant with this policy by the study period and this measure was associated with a seroprotection in 33-100% of patients after a single booster dose of vaccine.
- Centers for Disease Control and Prevention. Ten
Great Public Health Achievements - United States, 1900-1999. MMWR Morb
Mortal Wkly Rep. 1999;48:241-3.
- Meisel R,
Toschke AM, Heiligensetzer C, Dilloo D, Laws HJ, Von Kries R. Increased
risk for invasive pneumococcal diseases in children with acute
lymphoblastic leukaemia. Br J Haematol. 2007;137:457-60. https://doi.org/10.1111/j.1365-2141.2007.06601.x PMid:17488489
V, Winqvist O, Blimark C, Langerbeins P, Chapel H, Dhalla F. Secondary
immunodeficiency in lymphoproliferative malignancies. Hematol Oncol.
2016;34:121-32. https://doi.org/10.1002/hon.2323 PMid:27402426
- Chinen J, Shearer WT. Secondary immunodeficiencies, including HIV infection. J Allergy Clin Immunol. 2010;125:S195-203. https://doi.org/10.1016/j.jaci.2009.08.040 PMid:20042227 PMCid:PMC6151868
M, Prince G, Biancotto A, Moir S, Kardava L, Santich BH, Cheung F,
Kotliarov Y, Chen J, Shi R, Zhou H, Golding H, Manischewitz J, King L,
Kunz LM, Noonan K, Borrello IM, Smith BD, Hourigan CS. Impaired B cell
immunity in acute myeloid leukemia patients after chemotherapy. J
Transl Med. 2017;15:155. https://doi.org/10.1186/s12967-017-1252-2 PMid:28693586 PMCid:PMC5504716
T, Mellander L, Andersson B, Abrahamsson J. Immune Reconstitution After
Childhood Acute Lymphoblastic Leukemia Is Most Severely Affected in the
High Risk Group. Pediatr Blood Cancer. 2005;44(5):461-8. https://doi.org/10.1002/pbc.20255 PMid:15558707
M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, Wingard JR,
Young JAH, Boeckh MJ. Guidelines for Preventing Infectious
Complications among Hematopoietic Cell Transplantation Recipients: A
Global Perspective. Biol Blood Marrow Transplant. 2009;15:1143-238. https://doi.org/10.1016/j.bbmt.2009.06.019 PMid:19747629 PMCid:PMC3103296
M, Cesaro S, de Lavallade H, Di Blasi R, Einarsdottir S, Gallo G,
Rieger C, Engelhard D, Lehrnbecher T, Ljungman P, Cordonnier C,
European Conference on Infections in Leukaemia group. Vaccination of
patients with haematological malignancies who did not have
transplantations: guidelines from the 2017 European Conference on
Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19:e188-99.
Epub 2019 Feb 8. https://doi.org/10.1016/S1473-3099(18)30601-7
C, Einarsdottir S, Cesaro S, Di Blasi R, Mikulska M, Rieger C, de
Lavallade H, Gallo G, Lehrnbecher T, Engelhard D, Ljungman P, European
Conference on Infections in Leukaemia group. Vaccination of
haemopoietic stem cell transplant recipients: guidelines of the 2017
European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect
Dis. 2019;19:e200-12. Epub 2019 Feb 8. https://doi.org/10.1016/S1473-3099(18)30600-5
degli Atti ML, Azzari C, Bartolozzi G, Esposito S, Fara GM, Giovanetti
F, Lo Giudice M. I correlati immunologici di protezione indotti dalle
vaccinazioni. Rivista di Immunologia e Allergologia Pediatrica.
2010;1:27-31. Available from: https://www.siaip.it/upload/riap/327_I%20correlati%20immunologici%20di%20protezione%20indotti%20dalle%20vaccinazioni.pdf
della Salute. Vaccinazioni dell'età pediatrica. Anno 2017 (coorte
2009). Coperture vaccinali (per 100 abitanti) per vaccinazioni eseguite
entro gli 8 anni, calcolate sui riepiloghi inviati dalle Regioni e
PP.AA. (per singolo antigene) [Internet]. [cited 2019 Jul 17].
Available from: http://www.salute.gov.it/imgs/C_17_tavole_20_allegati_iitemAllegati_4_fileAllegati_itemFile_6_file.pdf
M, Duse M. Guida pratica. Le immunodeficienze nell'ambulatorio del
pediatra [Internet]. 2016 [cited 2019 Jul 17]. Available from: https://www.aip-it.org/sites/default/files/allegati-pagine/guidaimmunodeficienze.pdf
A, Bella A, Del Manso M, Baggieri M, Magurano F, Rota MC. Ongoing
outbreak with well over 4,000 measles cases in Italy from January to
end August 2017 − what is making elimination so difficult? Euro
Surveill. 2017;22. https://doi.org/10.2807/1560-7917.ES.2017.22.37.30614 PMid:28933342 PMCid:PMC5607657
K, Allwinn R, Langer R, Becker M, Keppler OT, Klingebiel T, Lehrnbecher
T. Differential loss of humoral immunity against measles, mumps,
rubella and varicella-zoster virus in children treated for cancer.
Vaccine. 2014;32:3357-61. https://doi.org/10.1016/j.vaccine.2014.04.042 PMid:24793952
M, Peracchi M, Tridello G, Pillon M, Fregonese F, D'Elia R, Zanesco L,
Cesaro S. Assessment of humoral immunity to poliomyelitis, tetanus,
hepatitis B, measles, rubella, and mumps in children after
chemotherapy. Cancer. 2004;101:635-41. https://doi.org/10.1002/cncr.20384 PMid:15274078
Yildirim Z, Buyukavci M. Assessment of Humoral Immunity to Hepatitis B,
Measles, Rubella, and Mumps in Children After Chemotherapy. J Pediatr
Hematol Oncol. 2018;40:e99-102. https://doi.org/10.1097/MPH.0000000000001072 PMid:29309372
SR, Bate J, Maple PA, Brown K, Breuer J, Heath PT. Varicella zoster
immune status in children treated for acute leukemia. Pediatr Blood
Cancer. 2014;61:2077-9. https://doi.org/10.1002/pbc.25086 PMid:24789692
HJ, Lee JW, Chung NG, Cho B, Kim HK, Kang JH. Assessment of serologic
immunity to diphtheria-tetanus- pertussis after treatment of Korean
pediatric hematology and oncology patients. J Korean Med Sci.
2012;27:78. https://doi.org/10.3346/jkms.2012.27.1.78 PMid:22219618 PMCid:PMC3247779
NY, Kandil SM, Boujettif K, Fouda AE. Assessment of hepatitis B virus
antibody titers in childhood cancer survivors. Eur J Pediatr.
2017;176:1269-73. https://doi.org/10.1007/s00431-017-2970-4 PMid:28730317
S, Vural S, Yildirmak Y, Urganci N, Usta M. Assessment of hepatitis B
immunization status after antineoplastic therapy in children with
cancer. Ann Saudi Med. 2011;31:573-6. https://doi.org/10.4103/0256-4947.87091 PMid:22048500 PMCid:PMC3221126
Tilburg CM, Sanders EA, Rovers MM, Wolfs TF, Bierings MB. Loss of
antibodies and response to (re-)vaccination in children after treatment
for acute lymphocytic leukemia: a systematic review. Leukemia.
2006;20:1717-22. https://doi.org/10.1038/sj.leu.2404326 PMid:16888619
der Kolk LE, Baars JW, Prins MH, van Oers MHJ. Rituximab treatment
results in impaired secondary humoral immune responsiveness. Blood.
2002;100:2257-9. https://doi.org/10.1182/blood.V100.6.2257 PMid:12200395
- Hua C, Barnetche T, Combe B, Morel J. Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: A systematic review and meta-analysis. Arthritis Care Res. 2014;66:1016-26. https://doi.org/10.1002/acr.22246 PMid:24339395
|Supplementary table 1. Univariate analysis of the number of lymphocytes in peripheral blood and the loss of protective antibody titers after chemotherapy.|
|Supplementary table 2. Presence of protective antibody titers after application of Vaccination Protocol, after chemotherapy.|
|Supplementary table 3. Vaccine immunity reconstitution in patients with lack of immunity after chemotherapy, after the application of Vaccination Protocol.|